PROK vs. CRBU
PROK (ProKidney Corp.) and CRBU (Caribou Biosciences, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, PROK returned -46.57%/yr vs -24.35%/yr for CRBU. At a 0.28 correlation, their price movements are largely independent.
Performance
PROK vs. CRBU - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PROK achieves a -17.41% return, which is significantly lower than CRBU's 29.87% return.
PROK
- 1D
- 6.94%
- 1M
- -3.65%
- YTD
- -17.41%
- 6M
- -28.02%
- 1Y
- 134.47%
- 3Y*
- -46.57%
- 5Y*
- —
- 10Y*
- —
CRBU
- 1D
- 3.25%
- 1M
- 6.99%
- YTD
- 29.87%
- 6M
- 6.44%
- 1Y
- 82.74%
- 3Y*
- -24.35%
- 5Y*
- —
- 10Y*
- —
PROK vs. CRBU - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
PROK ProKidney Corp. | -17.41% | 32.54% | -5.06% | -74.05% | -20.51% |
CRBU Caribou Biosciences, Inc. | 29.87% | 0.00% | -72.25% | -8.76% | -6.69% |
Correlation
The correlation between PROK and CRBU is 0.37, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.37 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.31 |
Correlation (All Time) Calculated using the full available price history since Jul 13, 2022 | 0.28 |
Fundamentals
PROK:
$262.56B
CRBU:
$197.95M
PROK:
-$0.00
CRBU:
-$1.41
PROK:
74.04K
CRBU:
22.09
PROK:
997.94
CRBU:
1.94
PROK:
$889.00K
CRBU:
$8.81M
PROK:
-$2.18M
CRBU:
$7.49M
PROK:
-$112.46M
CRBU:
-$115.23M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PROK vs. CRBU — Risk / Return Rank
PROK
CRBU
PROK vs. CRBU - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ProKidney Corp. (PROK) and Caribou Biosciences, Inc. (CRBU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| PROK | CRBU | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.74 | ||
| Sortino ratioReturn per unit of downside risk | +5.04 | ||
| Omega ratioGain probability vs. loss probability | 1.79 | 1.21 | +0.58 |
| Calmar ratioReturn relative to maximum drawdown | 1.93 | 1.63 | +0.30 |
| Martin ratioReturn relative to average drawdown | 2.55 | 2.87 | -0.33 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| PROK | CRBU | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.26 | 1.00 | -0.74 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.12 | -0.40 | +0.29 |
Drawdowns
PROK vs. CRBU - Drawdown Comparison
The maximum PROK drawdown since its inception was -96.29%, roughly equal to the maximum CRBU drawdown of -97.58%. Use the drawdown chart below to compare losses from any high point for PROK and CRBU.
Loading charts...
Drawdown Indicators
| PROK | CRBU | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.29% | -97.58% | +1.29% |
Max Drawdown (1Y)Largest decline over 1 year | -70.08% | -51.06% | -19.02% |
Max Drawdown (3Y)Largest decline over 3 years | -96.09% | -91.12% | -4.97% |
Current DrawdownCurrent decline from peak | -86.57% | -93.18% | +6.61% |
Average DrawdownAverage peak-to-trough decline | -65.10% | -79.28% | +14.18% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 52.99% | 28.89% | +24.10% |
Volatility
PROK vs. CRBU - Volatility Comparison
The current volatility for ProKidney Corp. (PROK) is 19.88%, while Caribou Biosciences, Inc. (CRBU) has a volatility of 21.68%. This indicates that PROK experiences smaller price fluctuations and is considered to be less risky than CRBU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PROK | CRBU | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 19.88% | 21.68% | -1.80% |
Volatility (6M)Calculated over the trailing 6-month period | 51.38% | 49.33% | +2.05% |
Volatility (1Y)Calculated over the trailing 1-year period | 525.53% | 83.40% | +442.13% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 284.71% | 86.82% | +197.89% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 284.71% | 86.82% | +197.89% |
Dividends
PROK vs. CRBU - Dividend Comparison
Neither PROK nor CRBU has paid dividends to shareholders.
Financials
PROK vs. CRBU - Financials Comparison
This section allows you to compare key financial metrics between ProKidney Corp. and Caribou Biosciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
PROK and CRBU have a correlation of 0.37, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CRBU has higher volatility (21.68%) compared to PROK (19.88%). In terms of maximum drawdown, PROK dropped -96.29% vs CRBU's -97.58%.
CRBU currently has the higher Sharpe Ratio (1.00 vs 0.26), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PROK and CRBU
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer